X

Drug Profile

Research programme: protein degrader therapeutics - Boehringer Ingelheim /Celeris Therapeutics

Alternative Names: Research programme: proximity-inducing compounds - Boehringer Ingelheim/Celeris Therapeutics

Latest Information Update: 18 Sep 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Boehringer Ingelheim; Celeris Therapeutics
Developer Boehringer Ingelheim
Class Small molecules
Mechanism of Action Proteolysis

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Research Unspecified

Most Recent Events

05 Apr 2022 Celeris Therapeutics enters into a collaboration with Boehringer Ingelheim to develop next-generation targeted protein degraders for unspecified indication
05 Apr 2022 Early research in Unspecified in Austria (unspecified) prior to September 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com